Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.17 EUR
Change Today +0.003 / 0.14%
Volume 22.7K
B8F On Other Exchanges
Symbol
Exchange
Xetra
London
As of 3:35 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

biofrontera ag (B8F) Snapshot

Open
€2.16
Previous Close
€2.17
Day High
€2.28
Day Low
€2.16
52 Week High
10/3/14 - €3.25
52 Week Low
08/24/15 - €1.66
Market Cap
51.2M
Average Volume 10 Days
37.7K
EPS TTM
€-0.58
Shares Outstanding
23.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOFRONTERA AG (B8F)

Related News

No related news articles were found.

biofrontera ag (B8F) Related Businessweek News

No Related Businessweek News Found

biofrontera ag (B8F) Details

Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatological-tested cosmetics for the treatment and care of diseased skin. The company’s products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, insect bites, burns, nuerodermatitis, and psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp’s natural balance; and Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities. It is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a serotonin receptor antagonist that is in Phase I clinical trial to treat migraine prophylaxis. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

54 Employees
Last Reported Date: 08/14/15
Founded in 1997

biofrontera ag (B8F) Top Compensated Officers

Co-Founder, Chairman of Management Board and ...
Total Annual Compensation: €405.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €202.0K
Compensation as of Fiscal Year 2014.

biofrontera ag (B8F) Key Developments

Biofrontera AG Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015; Provides Revenue Guidance for the Year Ending December 31, 2015

Biofrontera AG reported unaudited consolidated earnings results for the six months ended June 30, 2015. For the period, the company reporting an increase in revenues by 29% to EUR 1.57 million against EUR 1.22 million a year ago. Significant growth in sales revenue of 29% compared to the same period in the previous year. Improving sales performance in European countries outside German home market. Consolidated loss before tax was EUR 7.3 million, reflecting FDA submission fee. The majority of revenues were again recorded in Germany with EUR 1.19 million against EUR 915,000 a year ago, which represents an increase of 30%. Product revenues in other European countries also developed well with EUR 382,000 being achieved, which represents an increase of 65% compared to the first half of the previous year. The company reported a net loss before tax of EUR 7.3 million against EUR 5.4 million a year ago, which includes development costs of EUR 4.5 million against EUR 2.1 million a year ago. The increase was primarily as a result of the application fee of EUR 2.1 million which was paid to the FDA. This amount may be repaid by the FDA as Biofrontera may be eligible for a waiver for small businesses. For the year ending December 31, 2015, the company targets for revenue development and can confirm annual growth expectation of 30% with revenue of EUR 4 million to EUR 5 million for the full year to December 31, 2015.

Biofrontera AG, H1 2015 Earnings Call, Aug 14, 2015

Biofrontera AG, H1 2015 Earnings Call, Aug 14, 2015

Biofrontera AG Presents at 13th SCC Small Cap Conference, Aug-31-2015 04:30 PM

Biofrontera AG Presents at 13th SCC Small Cap Conference, Aug-31-2015 04:30 PM. Venue: DVFA Center, Mainzer Landstr. 37-039, 60329 Frankfurt am Main, Germany. Speakers: Hermann Lübbert, Co-Founder, Chairman of Management Board and Chief Executive Officer, Thomas Schaffer, Chief Financial Officer and Member of Management Board.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
B8F:GR €2.17 EUR +0.003

B8F Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for B8F.
View Industry Companies
 

Industry Analysis

B8F

Industry Average

Valuation B8F Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOFRONTERA AG, please visit www.biofrontera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.